Mantle cell lymphoma: Curcumin nanodisks and possible new concepts on drug delivery for an incurable lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 8, 2011, Pages 1418-1420

  Tadmor, Tamar ^a   Polliack, Aaron ^b  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CASPASE 3; CURCUMIN; CYCLIN D1; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; PREDNISONE; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; RITUXIMAB; TURMERIC; VINCRISTINE;

APOPTOSIS; B CELL LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CURCUMA LONGA; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; ENZYME ACTIVATION; FOOD DRUG INTERACTION; GENE OVEREXPRESSION; HUMAN; IMMUNOMODULATION; MANTLE CELL LYMPHOMA; NANODISK; NANOTECHNOLOGY; NONHUMAN; NOTE; PRIORITY JOURNAL; SURVIVAL TIME; TEA; TREATMENT OUTCOME;

APOPTOSIS; CURCUMIN; HUMANS; NANOSTRUCTURES; NANOTECHNOLOGY;

EID: 79960428351     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.577258     Document Type: Note

References (14)

1. Williams ME, Connors JM, Dreyling MH, et al. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma 2011;52:24-33
2. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27:1209-1213
3. Goy A, Kahl B. Mantle cell lymphoma: the promise of new treatment options. Crit Rev Oncol Hematol 2010 Dec 16. [Epub ahead of print]
4. Singh ATK, Ghosh M, Forte TM, Ryan RO, Gordon LI. Curcumin nanodisk-induced apoptosis in mantle cell lymphoma. Leuk Lymphoma 2011;52:1537-1543
5. Ben-Arye E, Attias S, Tadmor T, Schiff E. Herbs in hematooncological care: an evidence-based review of data on efficacy, safety, and drug interactions. Leuk Lymphoma 2010;51:1414-1423
6. Chen Y, Shu W, Chen W, Wu Q, Liu H, Cui G. Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells. Basic Clin Pharmacol Toxicol 2007;101:427-433 (Pubitemid 350135350)
7. Hussain AR, Ahmed M, Al-Jomah NA, et al. Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 2008;7:3318-3329
8. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and Ikappa B alpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003;101:1053-1062 (Pubitemid 36139379)
9. Gururajan M, Dasu T, Shahidain S, et al. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. J Immunol 2007;178:111-121 (Pubitemid 46033592)
10. Aggarwal BB, Sethi G, Baladandayuthapani V, Krishnan S, Shishodia S. Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J Cell Biochem 2007;102:580-592 (Pubitemid 47557413)
11. Rudelius M, Pittaluga S, Nishizuka S, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006;108:1668-1676 (Pubitemid 44316136)
12. Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nature Rev Clin Oncol 2011;8:85-96
13. Ghosh M, Singh ATK, Sulchek T, Gordon LI, Ryan RO. Curcumin nanodisks: formulation and characterization. Nanomedicine 2011;7:162-167
14. Redmond KA, Nguyen T-S, Ryan RO. All-trans-retinoic acid nanodisks. Int J Pharm 2007;339:246-250 (Pubitemid 46977599)